735 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates http://www.zacks.com/stock/news/557902/3-big-drug-biotech-stocks-set-to-beat-q3-earnings-estimates?cid=CS-ZC-FT-earnings_esp-557902 Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
Has Amgen (AMGN) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/553022/has-amgen-amgn-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-553022 Oct 07, 2019 - Is (AMGN) Outperforming Other Medical Stocks This Year?
Merck's Pediatric Filings for Dificid Get FDA's Priority Review http://www.zacks.com/stock/news/547611/mercks-pediatric-filings-for-dificid-get-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547611 Oct 03, 2019 - The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN) http://www.zacks.com/stock/news/545932/why-the-earnings-surprise-streak-could-continue-for-amgen-amgn?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-545932 Oct 02, 2019 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Ranked Income Stocks to Buy for October 2nd http://www.zacks.com/commentary/545738/top-ranked-income-stocks-to-buy-for-october-2nd?cid=CS-ZC-FT-zacks_#1_rank_additions-545738 Oct 02, 2019 - Top Ranked Income Stocks to Buy for October 2nd
Incyte Treats First Patient in Phase III Vitiligo Study http://www.zacks.com/stock/news/536926/incyte-treats-first-patient-in-phase-iii-vitiligo-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-536926 Sep 26, 2019 - Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More http://www.zacks.com/stock/news/535438/biotech-stock-roundup-pipeline-updates-from-regn-biib-amgn-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-535438 Sep 25, 2019 - Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent http://www.zacks.com/stock/news/532208/regeneron-sanofi-gets-positive-chmp-opinion-for-dupixent?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532208 Sep 23, 2019 - Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.
5 Safe Bets for a Rocky Market http://www.zacks.com/stock/news/528232/5-safe-bets-for-a-rocky-market?cid=CS-ZC-FT-analyst_blog|investment_ideas-528232 Sep 20, 2019 - Here are 5 companies with proven track records.
3 Big Biotech Stocks Worth Adding to Your Portfolio Now http://www.zacks.com/stock/news/527589/3-big-biotech-stocks-worth-adding-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|investment_ideas-527589 Sep 20, 2019 - We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.

Pages: 1234567...74

<Page 2>